Valeant Pharmaceuticals Intl Inc.: Is the Reward Worth the Risk?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has a plan to get out of debt, but it’s going to take pristine execution.

| More on:
The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you look at Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) the way I do, you likely feel equal parts greed and terror. On one hand, you see a stock that is trading at under $16 a share, when a year and a half ago, it was trading over $335 a share, so you dream of it returning to those sorts of prices. But, on the other hand, you’ve got a company carrying nearly US$30 billion in debt; if the company were to go into bankruptcy, investors would be left with nothing.

So, what should we do? Is the potential reward worth all the risk associated with Valeant?

It all depends on how the company does managing that debt going forward. Valeant owes US$2.6 billion in 2018, US$1.1 billion in 2019, US$7.7 billion in 2020, and US$3.2 billion in 2021 — not to mention the US$13.3 billion due in years following. In the next four years, Valeant has to pay US$14.6 billion, which is a huge mountain of debt for any company to overcome, but it’s especially concerning for Valeant because its revenue is dropping.

In 2015, Valeant had US$10.4 billion in revenue, but by the end of 2016, revenue dropped to US$9.6 billion. And, as is expected, the company had a significant net income loss of US$2.4 billion. But cash flow is what matters right now with regard to ensuring that its debt payments can be made and, for the most part, this is relatively constant. In 2015, Valeant had US$2.257 billion in cash flow; in 2016, cash flow dropped 8% to $2.087 billion. No one likes to see that happen, but there were also some asset sales that contributed to a reduction in total sales.

The question is, Can it manage that debt? The company paid down US$1.1 billion of its debt earlier this week thanks to some asset sales announced back in January. But, just as important, Valeant is looking to refinance some of that debt to hopefully make it more manageable. Remember, Valeant owes US$14.6 billion over the next four years. That’s a lot and doesn’t give the company much time to work on its turnaround strategy. Growth is possible at Valeant, but not with so much debt coming due in a few years’ time.

The company is hoping to refinance all of its loans that are due between now and 2022 and push them later. There are positives and negatives to this strategy. On the one hand, pushing debt out tends to make it more expensive, so theoretically, more interest will be charged (and interest rates are going up). On the other hand, this strategy will give the company some wiggle room, so it can execute its business plan. While there is no guarantee that this refinance will occur, I think it’s a generally positive step for the company.

You’re likely scratching your head and questioning whether you should buy Valeant or not. The answer is both yes and no. Valeant owns plenty of incredible assets that, when they reach scale, could generate growth. But it has a tonne of debt, which will hold it back until it is paid off. If you’re going to invest here, understand it’s a speculative trade. You could make a lot of money, but you could lose it all in liquidation. Tread carefully.

Should you invest $1,000 in Enbridge right now?

Before you buy stock in Enbridge, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Enbridge wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

Canada day banner background design of flag
Tech Stocks

The Top Canadian Stock to Buy With $5,000 in 2025

There are few Canadian stocks out there that offer the outlook of this tech stock, bound for more growth.

Read more »

A close up color image of a small green plant sprouting out of a pile of Canadian dollar coins "loonies."
Dividend Stocks

I’d Put $15,000 in These 3 Dividend-Growth Champions for Increasing Income Potential

Want to offset some volatility? Here are three defensive dividend-growth champions that can generate a juicy yield right now.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

Transform Your TFSA Into a Cash-Creating Machine With $7,000

Discover how the Tax-Free Savings Account can be your golden goose for generating cash without losing your investment.

Read more »

monthly desk calendar
Dividend Stocks

How I’d Invest $10,000 in Canadian Value Stocks for Monthly Dividend Income

A $10,000-diversified portfolio of value stocks focusing on dividend safety, yield, growth, and payment schedules can provide a reliable source…

Read more »

Canadian dollars are printed
Investing

How I’d Invest $1,000 Right Now for Long-Term Growth

These three Canadian stocks could deliver superior returns in the long run.

Read more »

a person watches a downward arrow crash through the floor
Dividend Stocks

Is This Correction Your Chance? Top 4 Canadian Dividend Stocks on Sale

Stocks may be down, but now is your chance to get some of these top dividend stocks on sale.

Read more »

open vault at bank
Bank Stocks

3 Canadian Bank Stocks to Shield Against Market Downturns

Canadian bank stocks are some of the best options on the market, and these three are probably the top ones.

Read more »